Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dexanabinol + nab-paclitaxel + gemcitabine
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous
01
Overview
This combination therapy consists of the synthetic cannabinoid derivative dexanabinol (ETS2101) administered alongside the standard-of-care chemotherapy doublet, nab-paclitaxel and gemcitabine. Dexanabinol is a non-psychotropic, non-competitive NMDA receptor antagonist that also inhibits TNF-alpha and NF-kappaB signaling. In the context of oncology, dexanabinol is hypothesized to act as a chemosensitizer, potentially enhancing the efficacy of cytotoxic agents by modulating the tumor microenvironment and reducing inflammatory signaling that contributes to resistance. nab-Paclitaxel is an albumin-bound formulation of paclitaxel that promotes microtubule assembly and prevents disassembly, while gemcitabine is a nucleoside analog that inhibits DNA synthesis. This triplet regimen has been primarily investigated in clinical trials for the treatment of advanced or metastatic pancreatic ductal adenocarcinoma (PDAC).
- Other names
- ETS2101 + nab-paclitaxel + gemcitabineHU-211 + nab-paclitaxel + gemcitabine
02
Targets
CDA (Cytidine deaminase)
Beyond the preview
Go deeper on dexanabinol + nab-paclitaxel + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dexanabinol + nab-paclitaxel + gemcitabine.